ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2666

Therapeutic Efficacy of Iguratimod in Patients with Primary Sjogren’s Syndrome

Lingshu Zhang1, Wei Jiang2, Cong-Qiu Chu3, Yi Liu4 and Yi Liu, 1Department of Rheumatology, West China Hospital, Sichuan University, Chengdu, China, 2The Ninth People's Hospital of Chongqing, Chongqing, China, 3Rheumatology, Oregon Health & Science University, Portland, OR, 4Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: B cells and Sjogren's syndrome

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: Sjögren's Syndrome - Poster II: Clinical Science

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Iguratimod (IGU), a methanesulfonanilide, has been used as a novel disease-modifying antirheumatic drug for treatment of rheumatoid arthritis in Japan and China. IGU displayed significantly inhibition of immunoglobulin production and suppression of IL-1, IL-6 and TNF. Previous studies have indicated an overt activation of B cells leading to the abnormal secretory function and accompanied by autoantibody production and hypergammaglobulinemia in Primary Sjögren’s Syndrome (pSS). The aim of this study was to investigate the efficacy of IGU in combination with conventional treatment in pSS and the effects of IGU on B cell activity.

Methods: A total of 50 female patients diagnosed with pSS meeting the international classification criteria (2002) were enrolled in this study, with a mean age of 29.3 ± 9.7 years. Active pSS patients were randomized (1:1) to conventional treatment (prednisone ≤ 10 mg daily, hydroxychloroquine 400mg daily and new hydrochloride bromide ethyl daily), or IGU treatment (conventional treatment plus IGU 50 mg daily). pSS disease activity was assessed using EULAR Sjögren’s syndrome disease activity index (ESSDAI) and EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI). Expression of CD135, IgD, CD38, CD20 and B cell activating factor-receptor (BAFF-R) on peripheral blood B cells were analyzed by flow cytometry in 20 pSS patients before and after treatment at 12 weeks.

Results: As shown in Table 1, at week 12, ESSDAI and ESSPRI were significantly improved but with a much greater gratitude in IGU treated group as compared with those in conventional treatment group (P<0.05). There were no obvious adverse events reported in either group. At baseline, pSS patients showed a significant increased expression of BAFF-R, CD38, CD135 and IgD on B cells compared with that in healthy controls. After 12 weeks of treatment, expression of BAFF-R, CD38, and IgD in IGU treatment group decreased significantly than that in conventional treatment group (Table 2) (P<0.05).

Conclusion:  In subjects with pSS, IGU treatment resulted in clinically meaningful improvements in disease activity compared with conventional therapy. IGU affected B cell frequency and functions in pSS via inhibition of BAFF-R expression on B cells and inhibition of B cell antibody production.

Table 1. Disease activity before and after treatment in pSS patients

 

IGU (n=25)

 

Conventional (n=25)

P1*

 

Before

After

P

Before

After

P

 

ESSPRI

6.3+1.5

2.9+ 1.4

<0.05

 

7.1 + 1.5

5.1+1.4

<0.05

<0.05

ESSDAI

13.7+ 2.4

6.4+1.8

<0.05

12.2+ 1.1

8.0+ 1.0

<0.05

<0.05

* P1 value represents comparison of changes after treatment between IGU and

Conventional groups.

 

Table 2. Expression of B cell markers before and after treatment in pSS patients

 

IGU (n=10)

 

Conventional (n=10)

P1*

 

Before

After

P

Before

After

P

 

BAFF-R (%)

92.5+ 3.4

69.4+ 5.4

<0.05

 

94.1+1.5

79.8+2.0

<0.05

<0.05

CD38,IgD (%)

74.9+ 10.4

43.4+8.8

<0.05

80.6+6.1

60.2+10

<0.05

<0.05

* P1 value represents comparison of changes after treatment between IGU and

Conventional groups.

 


Disclosure: L. Zhang, None; W. Jiang, None; C. Q. Chu, None; Y. Liu, None.

To cite this abstract in AMA style:

Zhang L, Jiang W, Chu CQ, Liu Y. Therapeutic Efficacy of Iguratimod in Patients with Primary Sjogren’s Syndrome [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/therapeutic-efficacy-of-iguratimod-in-patients-with-primary-sjogrens-syndrome/. Accessed April 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapeutic-efficacy-of-iguratimod-in-patients-with-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.